ノロウイルス治療の世界市場レポート2025年

ノロウイルス治療の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR10.7％で29億1,000万米ドルに成長します。この成長の主な要因としては、抗ウイルス薬研究への資金提供の増加、迅速診断ソリューションの普及拡大、公衆衛生上の懸念としてのノロウイルスの認知拡大、発展途上地域におけるヘルスケアアクセスの拡大、症状の重症度軽減を目的とした支持療法オプションの開発などが挙げられます。予測期間中に予想される顕著な動向は、ワクチンイノベーションの進展、新しい抗ウイルス治療法の開発、分子診断の強化、AIを搭載した診断システムの活用、公衆衛生イニシアチブの強化、手頃な価格のポイントオブケア治療オプションの導入です。

感染症の罹患率の上昇は、ノロウイルス治療市場の成長を促進すると予想されます。細菌、ウイルス、真菌、寄生虫によって引き起こされるこれらの疾患には、インフルエンザ、結核、HIV/AIDS、マラリア、ノロウイルスなどがあり、人々の間で急速に広がる可能性があります。都市の過密化は、人口密集地内での病原体の迅速な感染を可能にし、この動向に大きな役割を果たしています。ノロウイルス治療は、適切な水分補給、衛生管理、隔離などの実践を通じて、症状を効果的に管理し、感染拡大を抑えることで、このような病気の影響を軽減するのに役立ちます。例えば、2025年3月、世界保健機関（WHO）は、2023年には世界で1,080万人が結核に感染し、その内訳は男性600万人、女性360万人、子ども130万人であると報告しました。このような感染症負担の増大が、ノロウイルス治療市場の拡大に寄与しています。

ノロウイルス治療市場の企業は、標的免疫化を促進し、重症感染症に対する防御を改善し、ノロウイルス関連疾患の世界の影響を軽減するために、先進的なmRNAワクチンなどの革新的なソリューションにますます注力しています。これらのmRNAワクチンは、操作されたメッセンジャーRNAを使用して細胞に特定のタンパク質を産生させ、様々な病原体に対する安定性、有効性、適応性を高めた標的免疫反応を引き起こします。例えば、2024年10月、米国のバイオテクノロジー企業であるModerna Inc.は、英国保健安全保障局（UKHSA）と共同で、mRNAノロウイルス・ワクチン（mRNA-1403）の世界初の第3相臨床試験を英国で開始しました。このワクチンは、生きたウイルスを使用することなく、強固な免疫反応を刺激するウイルスタンパク質の生成を身体に促すことで、感染力の強いノロウイルスと闘うように設計されています。主な特徴としては、安定化mRNAの使用による耐久性の向上、進化するウイルス株に対応した迅速な開発能力、抗体とT細胞の両方の反応を誘発する能力などが挙げられます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のノロウイルス治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のノロウイルス治療市場：成長率分析
• 世界のノロウイルス治療市場の実績：規模と成長, 2019-2024
• 世界のノロウイルス治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界のノロウイルス治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のノロウイルス治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 電解質
• 静脈内輸液
• 解熱剤
• 鎮痛剤
• 下痢止め
• その他の治療法
• 世界のノロウイルス治療市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌培養検査
• 便検査
• その他の診断
• 世界のノロウイルス治療市場投与経路別：、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 皮下
• 世界のノロウイルス治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア設定
• 世界のノロウイルス治療市場電解質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口補水塩（ORS）
• スポーツドリンク
• 小児用電解質溶液
• 世界のノロウイルス治療市場静脈内輸液の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 晶質
• コロイド
• 乳酸リンゲル液
• 世界のノロウイルス治療市場解熱剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アセトアミノフェン（パラセタモール）
• イブプロフェン
• アスピリン
• 世界のノロウイルス治療市場鎮痛剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• オピオイド鎮痛薬
• アセトアミノフェン系鎮痛剤
• 世界のノロウイルス治療市場下痢止め薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロペラミド
• 次サリチル酸ビスマス
• ジフェノキシレート-アトロピン
• 世界のノロウイルス治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 制吐剤
• プロバイオティクス
• 亜鉛サプリメント

第7章 地域別・国別分析

• 世界のノロウイルス治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のノロウイルス治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ノロウイルス治療市場：競合情勢
• ノロウイルス治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Novartis AG
• AstraZeneca plc
• GSK plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Reckitt Benckiser Group plc
• Sun Pharmaceutical Industries Ltd.
• Lupin Ltd.
• Aurobindo Pharma Limited
• Cipla Inc.
• Endo International plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ノロウイルス治療市場2029：新たな機会を提供する国
• ノロウイルス治療市場2029：新たな機会を提供するセグメント
• ノロウイルス治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Norovirus treatment involves supportive care designed to alleviate symptoms like vomiting, diarrhea, and stomach pain caused by the virus. This care primarily focuses on maintaining hydration, getting adequate rest, and managing symptoms, as there is currently no specific antiviral medication available for norovirus.

Key components of norovirus treatment include electrolytes, intravenous fluids, antipyretics, analgesics, anti-diarrheal medications, and others. Electrolytes are essential minerals that carry an electric charge and play a crucial role in vital bodily functions such as nerve communication, muscle contractions, maintaining hydration, and regulating pH balance. Diagnostic approaches consist of stool tests, bacterial culture tests, and more. Routes of administration vary and include oral, intravenous, or subcutaneous methods, and these treatments are delivered across settings such as hospitals, clinics, and homecare environments.

The norovirus treatment market research report is one of a series of new reports from The Business Research Company that provides norovirus treatment market statistics, including the norovirus treatment industry global market size, regional shares, competitors with the norovirus treatment market share, detailed norovirus treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the norovirus treatment industry. This norovirus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The norovirus treatment market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. Growth during the historical period was driven by increasing global outbreaks of norovirus, heightened public awareness, a stronger emphasis on supportive care strategies, rising investments in vaccine development, improvements in healthcare infrastructure, and increased demand for efficient infection control practices.

The norovirus treatment market size is expected to see rapid growth in the next few years. It will grow to $2.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. Key factors contributing to this growth include increased funding for antiviral drug research, higher uptake of rapid diagnostic solutions, greater recognition of norovirus as a public health concern, expanded healthcare access in developing regions, and advancements in supportive care options aimed at reducing symptom severity. Prominent trends anticipated during the forecast period are progress in vaccine innovation, development of new antiviral treatments, enhancements in molecular diagnostics, utilization of AI-powered diagnostic systems, stronger public health initiatives, and the introduction of affordable point-of-care therapeutic options.

The rising incidence of infectious diseases is expected to drive the growth of the norovirus treatment market. These diseases, caused by bacteria, viruses, fungi, or parasites, include influenza, tuberculosis, HIV/AIDS, malaria, and norovirus, and can spread rapidly among people. Urban overcrowding plays a significant role in this trend by enabling faster transmission of pathogens within densely populated areas. Norovirus treatment helps mitigate the impact of such diseases by effectively managing symptoms and reducing spread through practices like proper hydration, hygiene, and isolation. For example, in March 2025, the World Health Organization reported that 10.8 million people globally were infected with tuberculosis in 2023, including 6.0 million men, 3.6 million women, and 1.3 million children. This growing burden of infectious diseases is contributing to the expansion of the norovirus treatment market.

Companies in the norovirus treatment market are increasingly focusing on innovative solutions such as advanced mRNA vaccines to promote targeted immunization, improve protection against severe infections, and reduce the global impact of norovirus-related illnesses. These mRNA vaccines use engineered messenger RNA to direct cells to produce specific proteins, eliciting a targeted immune response with enhanced stability, effectiveness, and adaptability against various pathogens. For instance, in October 2024, Moderna Inc., a US-based biotechnology company, in collaboration with the UK Health Security Agency (UKHSA), initiated the world's first Phase 3 clinical trial of an mRNA norovirus vaccine (mRNA-1403) in the UK. This vaccine is designed to combat the highly contagious norovirus by prompting the body to generate viral proteins that stimulate a robust immune response, without using the live virus. Key features include the use of stabilized mRNA for improved durability, the capacity for rapid development in response to evolving viral strains, and the ability to trigger both antibody and T-cell responses.

In March 2024, Kenvue Inc., a US-based consumer healthcare company, partnered with the Association of Physicians of India (API) to support public health awareness and preventive care efforts. Through this collaboration, Kenvue seeks to improve clinical guidance on hydration and energy management for hospitalized patients with non-diarrheal illnesses. The partnership aims to promote evidence-based recommendations developed jointly with API, a professional organization representing internal medicine physicians in India.

Major players in the norovirus treatment market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Sun Pharmaceutical Industries Ltd., Lupin Ltd., Aurobindo Pharma Limited, Cipla Inc., and Endo International plc.

North America was the largest region in the norovirus treatment market in 2024. The regions covered in norovirus treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the norovirus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The norovirus treatment market includes revenues earned by entities by providing services such as symptom management, rehydration therapy, and stool tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The norovirus treatment market also includes sales of oral rehydration solutions (ORS), anti-nausea medications, thermometers, disinfectants, and cleaning products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Norovirus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on norovirus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for norovirus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The norovirus treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Electrolytes; Intravenous Fluids; Antipyretics; Analgesics; Anti-Diarrheal; Other Treatments
• 2) By Diagnosis: Bacteria Culture Test; Stool Tests; Other Diagnosis
• 3) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 4) By End User: Hospitals; Clinics; Homecare Settings
• Subsegments:
• 1) By Electrolytes: Oral Rehydration Salts (ORS), Sports Drinks, Pediatric Electrolyte Solutions
• 2) By Intravenous Fluids: Crystalloids, Colloids, Lactated Ringer's Solution
• 3) By Antipyretics: Acetaminophen (Paracetamol), Ibuprofen, Aspirin
• 4) By Analgesics: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen-Based Analgesics
• 5) By Anti-Diarrheal: Loperamide, Bismuth Subsalicylate, Diphenoxylate-Atropine
• 6) By Other Treatments: Antiemetics, Probiotics, Zinc Supplements
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche Ltd.; Merck and Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Norovirus Treatment Market Characteristics

3. Norovirus Treatment Market Trends And Strategies

4. Norovirus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Norovirus Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Norovirus Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Norovirus Treatment Market Growth Rate Analysis
• 5.4. Global Norovirus Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Norovirus Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Norovirus Treatment Total Addressable Market (TAM)

6. Norovirus Treatment Market Segmentation

• 6.1. Global Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Electrolytes
• Intravenous Fluids
• Antipyretics
• Analgesics
• Anti-Diarrheal
• Other Treatments
• 6.2. Global Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacteria Culture Test
• Stool Tests
• Other Diagnosis
• 6.3. Global Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.4. Global Norovirus Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• 6.5. Global Norovirus Treatment Market, Sub-Segmentation Of Electrolytes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Rehydration Salts (ORS)
• Sports Drinks
• Pediatric Electrolyte Solutions
• 6.6. Global Norovirus Treatment Market, Sub-Segmentation Of Intravenous Fluids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Crystalloids
• Colloids
• Lactated Ringer's Solution
• 6.7. Global Norovirus Treatment Market, Sub-Segmentation Of Antipyretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acetaminophen (Paracetamol)
• Ibuprofen
• Aspirin
• 6.8. Global Norovirus Treatment Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Opioid Analgesics
• Acetaminophen-Based Analgesics
• 6.9. Global Norovirus Treatment Market, Sub-Segmentation Of Anti-Diarrheal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Loperamide
• Bismuth Subsalicylate
• Diphenoxylate-Atropine
• 6.10. Global Norovirus Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiemetics
• Probiotics
• Zinc Supplements

7. Norovirus Treatment Market Regional And Country Analysis

• 7.1. Global Norovirus Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Norovirus Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Norovirus Treatment Market

• 8.1. Asia-Pacific Norovirus Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Norovirus Treatment Market

• 9.1. China Norovirus Treatment Market Overview
• 9.2. China Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Norovirus Treatment Market

• 10.1. India Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Norovirus Treatment Market

• 11.1. Japan Norovirus Treatment Market Overview
• 11.2. Japan Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Norovirus Treatment Market

• 12.1. Australia Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Norovirus Treatment Market

• 13.1. Indonesia Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Norovirus Treatment Market

• 14.1. South Korea Norovirus Treatment Market Overview
• 14.2. South Korea Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Norovirus Treatment Market

• 15.1. Western Europe Norovirus Treatment Market Overview
• 15.2. Western Europe Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Norovirus Treatment Market

• 16.1. UK Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Norovirus Treatment Market

• 17.1. Germany Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Norovirus Treatment Market

• 18.1. France Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Norovirus Treatment Market

• 19.1. Italy Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Norovirus Treatment Market

• 20.1. Spain Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Norovirus Treatment Market

• 21.1. Eastern Europe Norovirus Treatment Market Overview
• 21.2. Eastern Europe Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Norovirus Treatment Market

• 22.1. Russia Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Norovirus Treatment Market

• 23.1. North America Norovirus Treatment Market Overview
• 23.2. North America Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Norovirus Treatment Market

• 24.1. USA Norovirus Treatment Market Overview
• 24.2. USA Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Norovirus Treatment Market

• 25.1. Canada Norovirus Treatment Market Overview
• 25.2. Canada Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Norovirus Treatment Market

• 26.1. South America Norovirus Treatment Market Overview
• 26.2. South America Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Norovirus Treatment Market

• 27.1. Brazil Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Norovirus Treatment Market

• 28.1. Middle East Norovirus Treatment Market Overview
• 28.2. Middle East Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Norovirus Treatment Market

• 29.1. Africa Norovirus Treatment Market Overview
• 29.2. Africa Norovirus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Norovirus Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Norovirus Treatment Market, Segmentation By Route Of Administration:, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Norovirus Treatment Market Competitive Landscape And Company Profiles

• 30.1. Norovirus Treatment Market Competitive Landscape
• 30.2. Norovirus Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Norovirus Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. Abbott Laboratories
• 31.5. Novartis AG
• 31.6. AstraZeneca plc
• 31.7. GSK plc
• 31.8. Eli Lilly and Company
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Reckitt Benckiser Group plc
• 31.11. Sun Pharmaceutical Industries Ltd.
• 31.12. Lupin Ltd.
• 31.13. Aurobindo Pharma Limited
• 31.14. Cipla Inc.
• 31.15. Endo International plc

32. Global Norovirus Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Norovirus Treatment Market

34. Recent Developments In The Norovirus Treatment Market

35. Norovirus Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Norovirus Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Norovirus Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Norovirus Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer